Abstract
CGRP and adrenomedullin [AM] are peptides that have a number of physiological effects, including vasodilation, through the activation of a shared GPCR, the family B calcitonin receptor-like receptor [CLR]. Specificity to each ligand is conferred through the unusual association of CLR with a single transmembrane accessory protein. For CGRP this is receptor activity-modifying protein 1 [RAMP1] and for AM acting at the AM1 receptor this is RAMP2. Receptor signalling by two specific peptide ligands through a common GPCR provides researchers with vital and unique information into similarities and differences of GPCR activation. Understanding the structure and function of these receptors will also provide a platform for future drug design for a number of cardiovascular and metabolic diseases in which CGRP and AM have been implicated. This review summarises the latest information and data concerning ligand binding, receptor activation and structural studies for both the CGRP and AM receptors.
Keywords: CGRP, adrenomedullin, AM, GPCR, CLR, RAMP, family B, receptor activation.
Current Protein & Peptide Science
Title:Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Volume: 14 Issue: 5
Author(s): Michael J. Woolley and Alex C. Conner
Affiliation:
Keywords: CGRP, adrenomedullin, AM, GPCR, CLR, RAMP, family B, receptor activation.
Abstract: CGRP and adrenomedullin [AM] are peptides that have a number of physiological effects, including vasodilation, through the activation of a shared GPCR, the family B calcitonin receptor-like receptor [CLR]. Specificity to each ligand is conferred through the unusual association of CLR with a single transmembrane accessory protein. For CGRP this is receptor activity-modifying protein 1 [RAMP1] and for AM acting at the AM1 receptor this is RAMP2. Receptor signalling by two specific peptide ligands through a common GPCR provides researchers with vital and unique information into similarities and differences of GPCR activation. Understanding the structure and function of these receptors will also provide a platform for future drug design for a number of cardiovascular and metabolic diseases in which CGRP and AM have been implicated. This review summarises the latest information and data concerning ligand binding, receptor activation and structural studies for both the CGRP and AM receptors.
Export Options
About this article
Cite this article as:
Woolley J. Michael and Conner C. Alex, Comparing the Molecular Pharmacology of CGRP and Adrenomedullin, Current Protein & Peptide Science 2013; 14 (5) . https://dx.doi.org/10.2174/13892037113149990053
DOI https://dx.doi.org/10.2174/13892037113149990053 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design Phytochemical and Pharmacological Insight on Sesamol: An Updated Review
Current Bioactive Compounds Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription
Current Drug Metabolism Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery The Validity of Chemical Analytical Methods by the Example of the Heparin Product Recall
Current Pharmaceutical Analysis The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Patents in the Diagnosis and Therapy of Neurocardiogenic Syncope
Recent Patents on Cardiovascular Drug Discovery Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Mexiletine Metabolites: A Review
Current Medicinal Chemistry Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology Recent Applications of Nanomaterials Based on Electrochemical Drug Analysis
Current Analytical Chemistry